+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1297538-32-9
1297538-32-9,MFCD29472270
Catalog No.:AA000TJW

1297538-32-9 | Odm-201

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$7.00   $5.00
- +
2mg
98%
in stock  
$11.00   $8.00
- +
5mg
98%
in stock  
$14.00   $10.00
- +
25mg
98%
in stock  
$33.00   $23.00
- +
50mg
98%
in stock  
$52.00   $36.00
- +
250mg
98%
in stock  
$112.00   $78.00
- +
1g
98%
in stock  
$309.00   $217.00
- +
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA000TJW
Chemical Name:
Odm-201
CAS Number:
1297538-32-9
Molecular Formula:
C19H19ClN6O2
Molecular Weight:
398.8462
MDL Number:
MFCD29472270
SMILES:
N#Cc1ccc(cc1Cl)c1ccn(n1)C[C@@H](NC(=O)c1n[nH]c(c1)C(O)C)C
Properties
Computed Properties
 
Complexity:
598  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
6  
Undefined Atom Stereocenter Count:
1  
XLogP3:
1.8  

Upstream Synthesis Route

[1]Patent:WO2016/162604,2016,A1,.Locationinpatent:Page/Pagecolumn17

[1]Patent:US2014/94474,2014,A1,.Locationinpatent:Page/Pagecolumn

[2]Patent:WO2018/162793,2018,A1,.Locationinpatent:Page/Pagecolumn12

[1]Patent:WO2016/162604,2016,A1,

[1]Patent:WO2016/162604,2016,A1,

[1]Patent:WO2016/162604,2016,A1,

Downstream Synthesis Route

[1]CurrentPatentAssignee:ORIONOYJ-US2014/94474,2014,A1Locationinpatent:Page/Pagecolumn

[2]CurrentPatentAssignee:ORIONSRL-WO2018/162793,2018,A1Locationinpatent:Page/Pagecolumn12

[1]CurrentPatentAssignee:ORIONOYJ-US2014/94474,2014,A1Locationinpatent:Page/Pagecolumn

[1]CurrentPatentAssignee:ORIONOYJ-WO2016/162604,2016,A1

[2]Yu,Jiang;Zhou,Peiting;Hu,Mingxing;Yang,Liuqing;Yan,Guoyi;Xu,Ruixue;Deng,Yufang;Li,Xinghai;Chen,Yuanwei[EuropeanJournalofMedicinalChemistry,2019,vol.182]

[3]CurrentPatentAssignee:WUHANJIUZHOUYUMINPHARMACEUTICALTECH-CN111116476,2020,A

[4]CurrentPatentAssignee:ZHEJIANGNORMALUNIVERSITY-CN113861115,2021,A

[5]Xu,Qian;Zhang,Zixiong;Huang,Chenchao;Bao,Qiqi;Zhang,Rongyu;Wu,Meng;Xiao,Xiaohui;Han,Xiaoli;Li,Xiaoyu;Zhou,Jinming[BioorganicChemistry,2022,vol.124]

[1]CurrentPatentAssignee:ORIONOYJ-WO2016/162604,2016,A1

[2]Yu,Jiang;Zhou,Peiting;Hu,Mingxing;Yang,Liuqing;Yan,Guoyi;Xu,Ruixue;Deng,Yufang;Li,Xinghai;Chen,Yuanwei[EuropeanJournalofMedicinalChemistry,2019,vol.182]

[3]CurrentPatentAssignee:NANJINGJUNRUOBIOMEDICALRESINSTITUTE;JIANGSUJUNRUOPHARMACEUTICAL;HAIMENBAIKANGPHARMACEUTICAL-CN110590668,2019,A

[4]CurrentPatentAssignee:WUHANJIUZHOUYUMINPHARMACEUTICALTECH-CN111116476,2020,A

[5]CurrentPatentAssignee:ZHEJIANGNORMALUNIVERSITY-CN113861115,2021,A

[6]Xu,Qian;Zhang,Zixiong;Huang,Chenchao;Bao,Qiqi;Zhang,Rongyu;Wu,Meng;Xiao,Xiaohui;Han,Xiaoli;Li,Xiaoyu;Zhou,Jinming[BioorganicChemistry,2022,vol.124]

[1]CurrentPatentAssignee:ORIONOYJ-WO2016/162604,2016,A1

[2]Yu,Jiang;Zhou,Peiting;Hu,Mingxing;Yang,Liuqing;Yan,Guoyi;Xu,Ruixue;Deng,Yufang;Li,Xinghai;Chen,Yuanwei[EuropeanJournalofMedicinalChemistry,2019,vol.182]

[3]CurrentPatentAssignee:JIANGSUJUNRUOPHARMACEUTICAL;NANJINGJUNRUOBIOMEDICALRESINSTITUTE;HAIMENBAIKANGPHARMACEUTICAL-CN110590668,2019,A

[4]CurrentPatentAssignee:HANGZHOUCHEMINSPIRETECH-CN111087324,2020,A

[5]CurrentPatentAssignee:HANGZHOUCHEMINSPIRETECH-CN111087324,2020,A

[6]CurrentPatentAssignee:HANGZHOUCHEMINSPIRETECH-CN111087324,2020,A

[7]CurrentPatentAssignee:HANGZHOUCHEMINSPIRETECH-CN111087324,2020,A

[8]CurrentPatentAssignee:ZHEJIANGNORMALUNIVERSITY-CN113861115,2021,A

[9]Bao,Qiqi;Han,Xiaoli;Huang,Chenchao;Li,Xiaoyu;Wu,Meng;Xiao,Xiaohui;Xu,Qian;Zhang,Rongyu;Zhang,Zixiong;Zhou,Jinming[BioorganicChemistry,2022,vol.124]

Literature

Title: Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms toandrogen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1297538-32-9
Building Blocks
More >
Tags:1297538-32-9 Molecular Formula|1297538-32-9 MDL|1297538-32-9 SMILES|1297538-32-9 Odm-201